Trial Profile
Non-Interventional study on treatment with Lipegfilgrastim (Lonquex®) in patients with urological malignant entities, being treated with myelotoxic chemotherapies. - NIS Lonquex URO
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Lipegfilgrastim (Primary)
- Indications Bladder cancer; Prostate cancer
- Focus Therapeutic Use
- Acronyms NIS Lonquex URO
- 14 Jan 2019 Status changed from recruiting to completed.
- 15 Sep 2016 New trial record